Evidence map›Paper›PMID 35804041›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2022

Primary adult sellar SMARCB1/INI1-deficient tumor represents a subtype of atypical teratoid/rhabdoid tumor.

Zejun Duan, Kun Yao, Shaomin Yang, Yanming Qu, Ming Ren, Yongli Zhang, Tao Fan, Heqian Zhao, Jie Gao, Jing Feng and 2 more

Abstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Brain Tumor Classification by Methylation Profile.Journal of Korean medical science · 2023
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zejun Duan *Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Kun Yao *Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Shaomin YangDepartment of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing, 100191, China.
Yanming QuDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Ming RenDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Yongli ZhangDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Tao FanDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Heqian ZhaoDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Jie GaoDepartment of Radiology, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Jing FengBeijing Key Laboratory of Gene Resource and Molecular Development, Laboratory of Neuroscience and Brain Development, School of Life Sciences, Beijing Normal University, Beijing, 100875, China.
Xiaolong FanBeijing Key Laboratory of Gene Resource and Molecular Development, Laboratory of Neuroscience and Brain Development, School of Life Sciences, Beijing Normal University, Beijing, 100875, China.
Xueling QiDepartment of Pathology, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China. xszqxl169@mail.ccmu.edu.cn.ORCID 0000-0002-5787-4951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loss of function in SMARCB1/INI1 has been observed in a group of malignancies collectively defined as SMARCB1/INI1-deficient neoplasms. Primary intracranial SMARCB1/INI1-deficient tumors in adults are extremely rare. We collected eight primary adult sellar SMARCB1/INI1-deficient tumors to study their clinicopathological and (epi)genetic characteristics. We performed a comprehensive assessment of the clinical, radiological, morphological and immunohistochemical features. FISH analysis for the SMARCB1 locus and target exome sequencing for 425 cancer relevant genes were performed. Furthermore, six bona fide proximal epithelioid sarcoma (PES), fourteen atypical teratoid/rhabdoid tumors (ATRT) in brain and five pediatric poorly differentiated chordomas (PDC) in the clivus were collected for comparative analysis of differential diagnostic maker expression and DNA methylation profile. The median age was 47.1 years, ranging from 26 to 73 years. On morphology, tumors were characterized by sheets of monomorphic larger epithelioid-like cells, in two cases with rhabdoid cells. "Stag-horn" vasculatures were observed in five cases. The loss of INI1 protein expression, co-expression of epithelial makers and mesenchymal markers were observed in all cases. CD34 expression was observed in six cases. Heterozygous deletion of SMARCB1/INI1 was confirmed using FISH in six cases. The results of target exome sequencing showed three patients harbored heterozygous point mutations in SMARCB1. The epigenetic features of the primary adult sellar SMARCB1/INI1-deficient tumors resembled the ATRT-MYC subgroup, but clustered apart from PES and PDC. Based on epigenetic characteristics, primary adult sellar SMARCB1/INI1-deficient tumors represent a subtype of ATRT with similar epigenetic characteristics of ATRT-MYC subgroup. Our findings suggest that DNA methylation profiling should be utilized for differential diagnosis for the majority of epithelioid sarcoma and (sellar) rhabdoid tumor.

Indexed as

Brain NeoplasmsChordomaRhabdoid TumorSarcomaDiagnosis, DifferentialHumansSMARCB1 ProteinSMARCB1 ProteinSMARCB1 protein, human

Identifiers

PMID35804041
PMCPMC9708584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.